Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Last trade$0.7316
Day change-$0.086 (-10.52%)
Day range$0.71 – $0.86
Volume1,689,047
Market cap$76M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$76.01M
Price / earnings
—
Price / book
0.68×
Price / sales
—
EV / sales
—
EV / EBITDA
2.44×
Profitability
Earnings per share
-$0.14
Return on assets
-10.84%
Return on equity
-11.58%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
15.62×
Quick ratio
15.62×
Cash ratio
15.38×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$29.29M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AVXL, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
-$2.03M
$2.29M
$2.13M
$3.55M
$4.5M
$2.62M
$3.15M
$2.66M
Research and development
-$4.71M
$4.19M
$4.66M
$7.29M
$9.96M
$9.89M
$10.45M
$11.61M
Total operating expenses
-$6.74M
$6.48M
$6.78M
$10.84M
$14.46M
$12.51M
$13.59M
$14.27M
Operating income
$6.74M
-$6.48M
-$6.78M
-$10.84M
-$14.46M
-$12.51M
-$13.59M
-$14.27M
Interest expense
$0
$0
$1.08M
$999K
$0
$0
$1.39M
$1.76M
Income before taxes
$7.82M
-$5.34M
-$5.66M
-$9.83M
-$13.24M
-$11.2M
-$12.11M
-$11.62M
Income taxes
$0
$0
$18K
$0
$0
$0
$0
$0
Net income
$7.82M
-$5.34M
-$5.68M
-$9.83M
-$13.24M
-$11.2M
-$12.11M
-$11.62M
Net income attributable to common shareholders
$7.82M
-$5.34M
-$5.68M
-$9.83M
-$13.24M
-$11.2M
-$12.11M
-$11.62M
EBITDA
$6.74M
-$6.48M
-$6.78M
-$10.84M
-$14.46M
-$12.51M
-$13.59M
-$14.27M
Basic earnings per share
$0.08
-$0.06
-$0.06
-$0.11
-$0.16
-$0.13
-$0.14
-$0.14
Diluted earnings per share
$0.08
-$0.06
-$0.06
-$0.11
-$0.16
-$0.13
-$0.14
-$0.14
Recent news
Company coverage with links to the original publishers.
Rosen Law Firm reminds investors of Anavex Life Sciences Corp. (NASDAQ: AVXL) who purchased securities between November 26, 2025 and August 28, 2026 of the November 30, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Anavex made false statements regarding internal controls, understated regulatory challenges related to former CEO Christopher Missling's misconduct, and misrepresented business operations and prospects.
Rosen Law Firm reminds investors in Anavex Life Sciences Corp (NASDAQ: AVXL) of the November 30, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Anavex made false statements regarding internal controls, understated regulatory challenges related to former CEO Christopher Mieslinger's misconduct, and misrepresented the company's business prospects, resulting in investor damages when the truth emerged.
Rosen Law Firm reminds investors of Anavex Life Sciences Corp. (NASDAQ: AVXL) who purchased securities between November 26, 2025 and August 28, 2026 of the November 30, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Anavex made false and misleading statements regarding inadequate internal controls, understated regulatory challenges related to former CEO Christopher Missling's misconduct, and misrepresented the company's business and prospects.
Rosen Law Firm has filed securities class action lawsuits against Anavex Life Sciences Corp., Honeywell Aerospace Inc., and Gildan Activewear Inc., alleging false and misleading statements. The firm is seeking lead plaintiffs with a November 30, 2026 deadline. Investors who purchased securities during specified class periods may be eligible for compensation.
A class action lawsuit has been filed against Anavex Life Sciences Corp. for alleged securities violations between November 26, 2025 and August 28, 2026. The complaint alleges the company and its executives made false statements regarding adequate internal controls, understated regulatory challenges related to former CEO Christopher Missling's misconduct, and misrepresented business operations and prospects. Investors who suffered losses can apply to be lead plaintiff by November 30, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.